| Examiner | Number of Cases | 3YGR |
|---|---|---|
| Examiner Basquill | 465 | 42% |
| Examiner Cabral | 429 | 66% |
| Examiner Davis | 698 | 84% |
| Examiner Holt | 206 | 47% |
| Examiner Ketcham | 53 | 13% |
| Examiner Krinos | 0 | 0% |
| Examiner Li | 0 | 0% |
| Examiner Liu | 348 | 46% |
| Examiner Park | 310 | 49% |
| Examiner Pragani | 3 | 0% |
| Examiner Soroush (SPE) | 299 | 44% |
| Examiner Thomas | 357 | 29% |
| Examiner Yu | 296 | 19% |
| Art Unit 1614 | 3464 | 51% |
| Number | Class Description |
|---|---|
| 424 | Drug, bio-affecting and body treating compositions |
| 514 | Drug, bio-affecting and body treating compositions |
| 504 | Plant protecting and regulating compositions |
| 604 | Surgery |
| 623 | Prosthesis (i.e., artificial body members), parts thereof, or aids and accessories therefor |
| 435 | Chemistry: molecular biology and microbiology |
| 607 | Surgery: light, thermal, and electrical application |
| 128 | Surgery |
| 433 | Dentistry |
| 554 | Organic compounds -- part of the class 532-570 series |
Art Unit 1614's grant rate is lower than that of Group 1610 and lower than that of the USPTO.
Below is the grant rate timeline for Art Unit 1614, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.
Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.